- Home
- IPSC vs PRT Comparison
IPSC vs PRT Comparison
Compare IPSC & PRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- PRT
- Stock Information
- Founded
- IPSC 2019
- PRT 2017
- Country
- IPSC United States
- PRT United States
- Employees
- IPSC N/A
- PRT N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- PRT Oil & Gas Production
- Sector
- IPSC Health Care
- PRT Energy
- Exchange
- IPSC Nasdaq
- PRT Nasdaq
- Market Cap
- IPSC 49.6M
- PRT 47.6M
- IPO Year
- IPSC 2021
- PRT N/A
- Fundamental
- Price
- IPSC $0.60
- PRT $4.03
- Analyst Decision
- IPSC Strong Buy
- PRT
- Analyst Count
- IPSC 5
- PRT 0
- Target Price
- IPSC $3.33
- PRT N/A
- AVG Volume (30 Days)
- IPSC 1.0M
- PRT 32.9K
- Earning Date
- IPSC 08-07-2025
- PRT 08-08-2025
- Dividend Yield
- IPSC N/A
- PRT 10.78%
- EPS Growth
- IPSC N/A
- PRT 6.25
- EPS
- IPSC N/A
- PRT 0.45
- Revenue
- IPSC $114,898,000.00
- PRT $6,430,197.00
- Revenue This Year
- IPSC $1,064.82
- PRT N/A
- Revenue Next Year
- IPSC N/A
- PRT N/A
- P/E Ratio
- IPSC N/A
- PRT $8.77
- Revenue Growth
- IPSC 8286.72
- PRT 5.12
- 52 Week Low
- IPSC $0.34
- PRT $3.26
- 52 Week High
- IPSC $3.29
- PRT $4.63
- Technical
- Relative Strength Index (RSI)
- IPSC 55.47
- PRT 43.11
- Support Level
- IPSC $0.52
- PRT $4.00
- Resistance Level
- IPSC $0.57
- PRT $4.10
- Average True Range (ATR)
- IPSC 0.04
- PRT 0.10
- MACD
- IPSC 0.00
- PRT -0.02
- Stochastic Oscillator
- IPSC 66.10
- PRT 9.17
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.